Are you Dr. Wertheim?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 104 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
2450 S TELSHOR BLVD
Las Cruces, NM 88011
Summary
- Dr. Michael Wertheim, MD is an oncologist in Las Cruces, New Mexico. He is currently licensed to practice medicine in New Mexico and Florida. He is affiliated with Memorial Medical Center.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1983 - 1985
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1980 - 1983
State University of New York Downstate Medical Center College of MedicineClass of 1980
Certifications & Licensure
NM State Medical License 2023 - 2027
FL State Medical License 1985 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
- Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 01
- Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Start of enrollment: 2014 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 10 citationsBintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial.Alexander Spira, Michael S Wertheim, Edward J Kim, Benjamin Tan, Heinz-Josef Lenz
The Oncologist. 2023-02-08 - 77 citationsParsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.Andres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, Michael S. Wertheim, William Jeffery Edenfield
Blood. 2019-04-18 - 373 citationsRandomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung CancerDavid R. Spigel, Thomas Ervin, Rodryg Ramlau, Davey B. Daniel, J. Goldschmidt
Journal of Clinical Oncology. 2013-11-10
Professional Memberships
- Member
